Corindus seeking premarket clearance for CorPath GRX in neurovascular procedures
Corindus Vascular Robotics (NYSE American:CVRS) is seeking premarket clearance from the FDA to expand the use of the CorPath GRX System, a second-generation robotic platform, in neurovascular procedures.
In 2016, CorPath GRX received FDA clearance for use in percutaneous coronary procedures and in 2018, for peripheral vascular procedures.
“An expansion of CorPath GRX to treat neurovascular conditions would represent a major stepping stone towards our goal of revolutionizing stroke treatment,” Mark Toland, president and CEO, said in a statement.
“We believe that our current robotic platform will bring benefits to neurovascular procedures today and we will leverage our recent achievements in telerobotics and strong focus on technology development to build a remote stroke solution to tackle the challenge of access to care,” he added.
This would extend the reach of highly skilled specialists across the globe by granting remote access to patients suffering from life-altering diseases where access to care is limited and time to treatment is paramount.
Dr. Aquilla Turk, CMO, said applying the benefits of robotic precision to neurovascular intervention, while building a wealth of clinical knowledge and expertise, are key to preparing for a future of remote stroke treatment.
Corindus recently conducted the world’s first-in-human percutaneous coronary procedure from a remote location about 20 miles from the catheterization lab, solidifying its commitment to providing better patient care to underserved patient populations with geographic barriers to treatment.